Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mononuclear cells (Vinmec Healthcare System)
- Development stage
- Unknown
- Lead developer
- Vinmec Healthcare System
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Autologous bone marrow mononuclear cell (BMMNC) therapy is a cell-based regenerative treatment developed by the Vinmec Healthcare System for autism spectrum disorder (ASD). The therapy involves harvesting a patient's own bone marrow (typically from the iliac crest), isolating the mononuclear cell fraction (which includes hematopoietic stem cells, mesenchymal stem cells, and progenitor cells) via centrifugation, and administering the cells intrathecally. The proposed mechanism of action involves the immunomodulatory and paracrine effects of the transplanted cells, which may reduce neuroinflammation and promote neural repair or connectivity in the brain. Clinical evaluation has progressed through Phase 2 trials in Vietnam, showing improvements in social communication and behavioral symptoms.
- Other names
- BMMNCsautologous bone marrow stem cellsautologous bone marrow mononuclear stem cells
Beyond the preview
Go deeper on autologous bone marrow mononuclear cells (Vinmec Healthcare System).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mononuclear cells (Vinmec Healthcare System).